Analysis of programmed death-ligand 1 (PD-L1) expression, transforming growth factor (TGF)-β gene expression signatures (GES) and tumor-infiltrating immune cells (IC) in hepatocellular carcinoma (HCC): Rationale for targeting PD-L1-and TGF-β

被引：0

作者：

Zhang, Y. ^{[1
]}

Naughton, B. J. ^{[2
]}

Rolfe, P. A. ^{[1
]}

Frick-Krieger, E. ^{[3
]}

Dussault, I. ^{[4
]}

Terracciano, L. ^{[5
]}

Ihling, C. ^{[6
]}

机构：

[1] EMD Serono Res & Dev Inst, R&D Global Early Dev, Billerica, MA USA

[2] EMD Serono Res & Dev Inst, Bioinformat, Billerica, MA USA

[3] Merck KGaA, RD EBP H, Darmstadt, Germany

[4] EMD Serono Res & Dev Inst, Clin Biomarkers & Compan Diagnost, Billerica, MA USA

[5] Univ Hosp Basel, Inst Pathol, Pathol, Basel, Switzerland

[6] Merck KGaA, CBD, Darmstadt, Germany

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1645P

引用

页数：1

共 50 条

[1] Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment
Lu, Li-Chun
Lee, Yi-Hsuan
Chang, Chun-Jung
Shao, Yu-Yun
Liu, Tsung-hao
Cheng, Ann-Lii
Hsu, Chih-Hung
CANCER RESEARCH, 2017, 77
[2] Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer
Pourali, Ghazaleh
Zafari, Nima
Velayati, Mahla
Mehrabadi, Shima
Maftooh, Mina
Hassanian, Seyed Mahdi
Mobarhan, Majid Ghayour
Ferns, Gordon A.
Avan, Amir
Khazaei, Majid
CURRENT DRUG TARGETS, 2023, 24 (17) : 1335 - 1345
[3] ASSOCIATION BETWEEN PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION AND GENE SIGNATURES OF RESPONSE OR RESISTANCE TO TISLELIZUMAB MONOTHERAPY IN HEPATOCELLULAR CARCINOMA (HCC)
Hou, Ming-Mo
Rau, Kun-Ming
Kang, Yoon-Koo
Lee, Jong-Seok
Pan, Hongming
Yuan, Ying
Yu, Cunjing
Zhang, Yun
Ma, Xiaopeng
Wu, Xikun
Li, Xin
Wood, Katie
Yen, Chia-Jui
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A47 - A48
[4] PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN PHEOCHROMOCYTOMA
Hashimoto, Yasuhiro
Imai, Atsushi
Hatakeyama, Shingo
Yoneyama, Takahiro
Koie, Takuya
Ohyama, Chikara
JOURNAL OF UROLOGY, 2017, 197 (04): : E474 - E474
[5] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
Imanishi, Naoko
Hirai, Ayako
Yoneda, Kazue
Shimajiri, Shohei
Kuwata, Taiji
Tashima, Yuko
Takeuchi, Masahiro
Iwai, Yoshiko
Ichiki, Yoshinobu
Tanaka, Fumihiro
JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
[6] Dual targeting of TGF-ß and PD-L1 inhibits tumor growth in TGF-ß/PD-L1-driven colorectal carcinoma
Khalili-Tanha, Ghazaleh
Fiuji, Hamid
Gharib, Masoumeh
Moghbeli, Meysam
Khalili-Tanha, Nima
Rahmani, Farzad
Shakour, Neda
Maftooh, Mina
Hassanian, Seyed Mahdi
Asgharzadeh, Fereshteh
Shahidsales, Soodabeh
Anvari, Kazem
Mozafari, M. R.
Ferns, Gordon A.
Batra, Jyotsna
Giovannetti, Elisa
Khazaei, Majid
Avan, Amir
LIFE SCIENCES, 2023, 328
[7] Programmed death-ligand 1 (PD-L1) expression in pheochromocytoma.
Hashimoto, Yasuhiro
Yamamoto, Hayato
Hatakeyama, Shingo
Yoneyama, Takahiro
Ohyama, Chikara
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[8] Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer
Kurozumi, Sasagu
Fujii, Takaaki
Matsumoto, Hiroshi
Inoue, Kenichi
Kurosumi, Masafumi
Horiguchi, Jun
Kuwano, Hiroyuki
MEDICAL MOLECULAR MORPHOLOGY, 2017, 50 (04) : 185 - 194
[9] Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer
Sasagu Kurozumi
Takaaki Fujii
Hiroshi Matsumoto
Kenichi Inoue
Masafumi Kurosumi
Jun Horiguchi
Hiroyuki Kuwano
Medical Molecular Morphology, 2017, 50 : 185 - 194
[10] Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
Valentine Suteau
Alexandre Collin
Philippe Menei
Patrice Rodien
Marie-Christine Rousselet
Claire Briet
Cancer Immunology, Immunotherapy, 2020, 69 : 2053 - 2061

← 1 2 3 4 5 →